Tardive Dyskinesia in Focus: Practical Strategies for Early Recognition and Coordinated Care

EP. 1: Quality-of-Life Impact and Clinical Burden in Tardive Dyskinesia
ByKayla Johnson, PharmD, BCPS, BCPP ,Julie Dopheide, PharmD, BCPP, FASHP, FAAPP ,Steven Stoner, PharmD, BCPP, FAAPP ,Bradley Burk, PharmD, BCPP Experts discuss practical strategies for early recognition and coordinated care of tardive dyskinesia to enhance patient outcomes and quality of life.

EP. 2: Risk Factors of Tardive Dyskinesia
ByKayla Johnson, PharmD, BCPS, BCPP ,Julie Dopheide, PharmD, BCPP, FASHP ,Steven Stoner, PharmD, BCPP, FAAPP ,Bradley Burk, PharmD, BCPP Health care professionals discuss the risks of tardive dyskinesia in patients on dopamine receptor antagonists and emphasize the importance of education and monitoring.

EP. 3: Improving Early Recognition of Tardive Dyskinesia
ByKayla Johnson, PharmD, BCPS, BCPP ,Julie Dopheide, PharmD, BCPP, FASHP, FAAPP ,Steven Stoner, PharmD, BCPP, FAAPP ,Bradley Burk, PharmD, BCPP In this episode, the panel focuses on how enhancing patient and clinician education can improve early recognition of tardive dyskinesia.

EP. 4: Screening for Tardive Dyskinesia With the Abnormal Involuntary Movement Scale
ByKayla Johnson, PharmD, BCPS, BCPP ,Julie Dopheide, PharmD, BCPP, FASHP, FAAPP ,Steven Stoner, PharmD, BCPP, FAAPP ,Bradley Burk, PharmD, BCPP In this episode, the panel explains how structured assessments such as the Abnormal Involuntary Movement Scale are essential tools for identifying tardive dyskinesia and distinguishing it from other drug-induced movement disorders.

EP. 5: Unmet Needs in Tardive Dyskinesia and Opportunities to Improve Early Recognition
ByKayla Johnson, PharmD, BCPS, BCPP ,Julie Dopheide, PharmD, BCPP, FASHP, FAAPP ,Steven Stoner, PharmD, BCPP, FAAPP ,Bradley Burk, PharmD, BCPP In this episode, panelists identify early recognition of tardive dyskinesia as a significant unmet need and describe key opportunities to improve screening.

EP. 6: Guiding Treatment Decisions After Tardive Dyskinesia Diagnosis
ByKayla Johnson, PharmD, BCPS, BCPP ,Julie Dopheide, PharmD, BCPP, FASHP, FAAPP ,Steven Stoner, PharmD, BCPP, FAAPP ,Bradley Burk, PharmD, BCPP In this episode, the panel discusses how clinicians determine whether treatment for tardive dyskinesia is warranted once abnormal movements are identified.

EP. 7: Therapeutic Approaches to Tardive Dyskinesia
ByKayla Johnson, PharmD, BCPS, BCPP ,Julie Dopheide, PharmD, BCPP, FASHP, FAAPP ,Steven Stoner, PharmD, BCPP, FAAPP ,Bradley Burk, PharmD, BCPP This episode outlines all treatment approaches available for tardive dyskinesia and how they are applied in practice.

EP. 8: VMAT2 Inhibitors in Tardive Dyskinesia
ByKayla Johnson, PharmD, BCPS, BCPP ,Julie Dopheide, PharmD, BCPP, FASHP ,Steven Stoner, PharmD, BCPP, FAAPP ,Bradley Burk, PharmD, BCPP In this episode, the panel explains how VMAT2 inhibitors became the foundation of modern tardive dyskinesia treatment.

EP. 9: Efficacy and Safety of Deutetrabenazine and Valbenazine in Tardive Dyskinesia
ByKayla Johnson, PharmD, BCPS, BCPP ,Julie Dopheide, PharmD, BCPP, FASHP ,Steven Stoner, PharmD, BCPP, FAAPP ,Bradley Burk, PharmD, BCPP In this episode, the panel reviews the efficacy and safety data supporting deutetrabenazine and valbenazine for tardive dyskinesia.

EP. 10: Treatment Selection and Dosing in Tardive Dyskinesia
ByKayla Johnson, PharmD, BCPS, BCPP ,Julie Dopheide, PharmD, BCPP, FASHP ,Steven Stoner, PharmD, BCPP, FAAPP ,Bradley Burk, PharmD, BCPP In this episode, the panel discusses key considerations for selecting and dosing VMAT2 inhibitors in tardive dyskinesia.

EP. 11: Strategies for Supporting Patient Adherence and Effective Communication in Tardive Dyskinesia
ByKayla Johnson, PharmD, BCPS, BCPP ,Julie Dopheide, PharmD, BCPP, FASHP ,Steven Stoner, PharmD, BCPP, FAAPP ,Bradley Burk, PharmD, BCPP In this episode, the panel discusses how pharmacists and the broader care team can support adherence and strengthen communication when patients start deutetrabenazine or valbenazine.

EP. 12: Pharmacist-Led Strategies for Early Tardive Dyskinesia Detection, Patient Support, and Collaborative Care
ByKayla Johnson, PharmD, BCPS, BCPP ,Julie Dopheide, PharmD, BCPP, FASHP ,Steven Stoner, PharmD, BCPP, FAAPP ,Bradley Burk, PharmD, BCPP In this episode, the panel reflects on how this program can help pharmacists strengthen their approach to tardive dyskinesia (TD) recognition and management.

EP. 13: Closing Thoughts on Pharmacists’ Role in Tardive Dyskinesia Management
ByKayla Johnson, PharmD, BCPS, BCPP ,Julie Dopheide, PharmD, BCPP, FASHP, FAAPP ,Steven Stoner, PharmD, BCPP, FAAPP ,Bradley Burk, PharmD, BCPP In this closing episode, the panel outlines practical steps pharmacists can take to support ongoing tardive dyskinesia monitoring across the care continuum.